SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma

BACKGROUND: Esophagogastric junction adenocarcinoma (EGJA) is a special malignant tumor with unknown biological behavior. PD-1 checkpoint inhibitors have been recommended as first-line treatment for advanced EGJA patients. However, the biomarkers for predicting immunotherapy response remain controve...

Descripción completa

Detalles Bibliográficos
Autores principales: OuYang, Li-Ying, Deng, Zi-Jian, You, Yu-Feng, Fang, Jia-Ming, Chen, Xi-Jie, Liu, Jun-Jie, Li, Xian-Zhe, Lian, Lei, Chen, Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424497/
https://www.ncbi.nlm.nih.gov/pubmed/36052090
http://dx.doi.org/10.3389/fimmu.2022.977894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424497/
https://www.ncbi.nlm.nih.gov/pubmed/36052090
http://dx.doi.org/10.3389/fimmu.2022.977894

Ejemplares similares